Eton Pharmaceuticals, Inc. (ETON)
| Market Cap | 1.70B +259.0% |
| Revenue (ttm) | 105.60M +81.5% |
| Net Income | 12.69M |
| EPS | 0.43 |
| Shares Out | 28.58M |
| PE Ratio | 140.18 |
| Forward PE | 40.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,109 |
| Open | 58.91 |
| Previous Close | 59.35 |
| Day's Range | 58.91 - 60.43 |
| 52-Week Range | 14.27 - 66.37 |
| Beta | 0.90 |
| Analysts | Strong Buy |
| Price Target | 71.00 (+19.29%) |
| Earnings Date | Aug 13, 2026 |
About ETON
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing vari... [Read more]
Financial Performance
In 2025, Eton Pharmaceuticals's revenue was $79.95 million, an increase of 104.94% compared to the previous year's $39.01 million. Losses were -$4.60 million, 20.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price target is $71.0, which is an increase of 19.29% from the latest price.
News
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals participates in a conference call with Craig-Hallum
Conference call with management to be held on August 18 at 1 pm hosted by Craig-Hallum.
Eton Pharmaceuticals reports Q2 non-GAAP EPS 43c, consensus 19c
Reports Q3 revenue $37.6M, consensus $27.12M. “Eton reported another outstanding quarter, delivering 99% year-over-year revenue growth, reflecting the strength of our rare disease portfolio and the ex...
Eton Pharmaceuticals sees FY26 revenue exceeding $145M consensus $121.32M
Sees at least a 35% adjusted EBITDA margin for FY26, an increase from prior guidance of at least 30%. The revised adjusted EBITDA guidance is inclusive of a $3M licensing…
Eton Pharmaceuticals price target raised to $70 from $65 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $70 from $65 and keeps a Buy rating on the shares. The company reported a material revenue beat,…
Eton Pharmaceuticals price target raised to $70 from $40 at B. Riley
B. Riley analyst Madison El-Saadi raised the firm’s price target on Eton Pharmaceuticals (ETON) to $70 from $40 and keeps a Buy rating on the shares. Eton delivered its strongest-ever…
Eton Pharmaceuticals price target raised to $68 from $60 at Canaccord
Canaccord raised the firm’s price target on Eton Pharmaceuticals (ETON) to $68 from $60 and keeps a Buy rating on the shares. The firm said Q2 was an impressive beat…
Eton Pharmaceuticals Earnings Call Transcript: Q2 2026
Record Q2 revenue and margin expansion were driven by HEMANGEOL and broad portfolio growth, prompting raised full-year guidance. Strategic acquisitions of ASN-001 and IMPAVIDO strengthen rare disease leadership, while robust cash flow supports continued investment and debt reduction.
Eton Pharmaceuticals Earnings release: Q2 2026
Eton Pharmaceuticals released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Eton Pharmaceuticals Quarterly report: Q2 2026
Eton Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 13, 2026.
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
DEER PARK, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals price target raised to $65 from $57 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Eton Pharmaceuticals (ETON) to $65 from $57 and keeps a Buy rating on the shares ahead of the Q2…
Eton Pharmaceuticals licenses U.S. rights to ASN-001 from Auson
Eton Pharmaceuticals (ETON) announced that the company has licensed U.S. rights to rare disease product candidate ASN-001 from Auson Pharmaceuticals. ASN-001 is under development for the treatment of ...
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
DEER PARK, Ill., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton reports results from new formulation of Khindivi study
Eton Pharmaceuticals (ETON) announced that the Company’s new formulation of KHINDIVI, or hydrocortisone, oral solution successfully showed bioequivalence to ALKINDI SPRINKLE, or hydrocortisone, oral g...
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
DEER PARK, Ill., July 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals price target raised to $62 from $40 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $62 from $40 and keeps a Buy rating on the shares. The firm cites the inclusion of Amglidia and…
Eton Pharmaceuticals initiated with a Buy at Canaccord
Canaccord last night initiated coverage of Eton Pharmaceuticals (ETON) with a Buy rating and $60 price target The firm says Eton is evolving into an ultra-rare disease company focused on…
Eton Pharmaceuticals initiated with a Buy at Canaccord
Canaccord initiated coverage of Eton Pharmaceuticals (ETON) with a Buy rating and $60 price target
Eton Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company is rapidly expanding its rare disease portfolio, aiming for 100 products and $500M+ peak sales by 2030. Key growth drivers include new product launches, label expansions, and a unique patient support program, with EBITDA margins expected to exceed 50% by 2028.
Eton Pharmaceuticals enters supply, distribution agreement for Impavido
Eton Pharmaceuticals (ETON) announced it has entered into a supply and distribution agreement for the United States commercialization rights to Impavido from an affiliate of Knight Therapeutics. Impav...
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
DEER PARK, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tre...
Eton Pharmaceuticals price target raised to $57 from $52 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $57 from $52 and keeps a Buy rating on the shares. The firm cites the company’s increased fiscal…
Eton Pharmaceuticals Earnings Call Transcript: Q1 2026
Record Q1 2026 sales and 73% product revenue growth led to raised full-year guidance above $120 million. New launches of HEMANGEOL and DESMODA, strong portfolio performance, and improved margins position the company for continued growth and profitability.